Trinity Annual Drug Index
Evaluating the Commercial Performances of Novel Drugs Approved in 2020
Home / Intelligence / White Papers / Trinity Annual Drug Index
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic value and R&D investment scores for each. 2020 saw 58 unique drug and biologic approvals, of which the majority were Oncology (29%) followed by Neurology (16%). In this report we describe the notable themes and trends within the industry and take a deeper look into a few products with outstanding performance. The COVID-19 pandemic, which swept the globe in 2020, brought unprecedented challenges and disruptions to the pharmaceutical industry, reshaping priorities and accelerating research efforts towards finding innovative solutions.
Interested in hearing expert discussion on this white paper?
View our on-demand webinar.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Picking Winners: Portfolio Management for a New Era
May 30, 2024 | 1:00 – 1:45 PM ET
Two additional sessions will be offered: June 4, 2024 | 16:00-16:45 (UTC+8:00) – Asia/ShanghaiJune 4, 2024 | 15:00-15:45 CET – Europe/Berlin Did you know 62% of products launched between September 2019 and December 2021 underperformed expectations in the first year of launch? What is going wrong, and how can we get it right? Join Trinity Life […]
Sign Up Now
White Papers
Picking Winners: Portfolio Management for a New Era
The biopharmaceutical industry is known for its promise of life-changing innovations, but many companies continue to advance the wrong therapies into the clinic, resulting in underperformance and wasted resources. This white paper explores the concentration of activity on well-trodden ground, and the lack of focus on true innovation. With increasing global pricing pressures and policy […]
Read More
Webinars
Learn From the Past – Launch Better Tomorrow
Available On Demand
Whether you are an emerging, mid-tier or large-tier company preparing for launch, this webinar is a must-watch. Join us for an informative webinar as our experts dive into Trinity Life Sciences’ latest white paper, the Trinity Annual Drug Index—an evaluation of commercial performance over three years of 58 novel drugs approved in 2020. Hear from […]
Watch Now